Tang Capital Management LLC Invests $2.43 Million in Atyr PHARMA INC (NASDAQ:ATYR)

Tang Capital Management LLC purchased a new stake in Atyr PHARMA INC (NASDAQ:ATYR) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 671,134 shares of the company’s stock, valued at approximately $2,430,000. Tang Capital Management LLC owned 0.80% of Atyr PHARMA at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the business. Group One Trading LLC bought a new stake in Atyr PHARMA in the 4th quarter valued at $26,000. Alterna Wealth Management Inc. bought a new stake in Atyr PHARMA in the 4th quarter valued at $36,000. Victory Capital Management Inc. bought a new stake in Atyr PHARMA in the 4th quarter valued at $37,000. Raymond James Financial Inc. bought a new stake in Atyr PHARMA in the 4th quarter valued at $39,000. Finally, JPMorgan Chase & Co. raised its stake in Atyr PHARMA by 52.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 31,440 shares of the company’s stock valued at $55,000 after acquiring an additional 10,754 shares during the period. Institutional investors own 61.72% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. Leerink Partners assumed coverage on Atyr PHARMA in a research note on Tuesday, February 18th. They issued an “outperform” rating and a $16.00 price target on the stock. HC Wainwright restated a “buy” rating and issued a $35.00 price target on shares of Atyr PHARMA in a research note on Friday, March 14th. Finally, Leerink Partnrs upgraded Atyr PHARMA to a “strong-buy” rating in a research report on Tuesday, February 18th. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $18.60.

Atyr PHARMA Stock Up 9.0%

ATYR stock opened at $3.27 on Friday. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.41 and a quick ratio of 5.41. The stock has a market capitalization of $291.04 million, a price-to-earnings ratio of -3.48 and a beta of 0.79. The business’s fifty day moving average price is $3.27 and its two-hundred day moving average price is $3.40. Atyr PHARMA INC has a fifty-two week low of $1.42 and a fifty-two week high of $4.66.

Atyr PHARMA (NASDAQ:ATYR) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.02. On average, equities analysts anticipate that Atyr PHARMA INC will post -0.91 earnings per share for the current year.

Atyr PHARMA Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.